Search Results for: DYNC1H1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ASB7 ankyrin repeat and SOCS box containing 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel ATP2B3 ATPase plasma membrane Ca2+ transporting 3
  • Reduction of cytosolic Ca++ levels
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Halothane
  • Desflurane
Novel ECSIT ECSIT signaling integrator
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Complex I biogenesis
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 cascade initiated on plasma membrane
Novel LMO4 LIM domain only 4
Novel MRE11 MRE11 homolog, double strand break repair nuclease
  • Cytosolic sensors of pathogen-associated DNA
  • DNA Damage/Telomere Stress Induced Senescence
  • IRF3-mediated induction of type I IFN
  • HDR through Single Strand Annealing (SSA)
  • HDR through MMEJ (alt-NHEJ)
  • HDR through Homologous Recombination (HRR)
  • Sensing of DNA Double Strand Breaks
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Meiotic recombination
  • DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome
  • Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2)
Novel PPP2R5C protein phosphatase 2 regulatory subunit B'gamma
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
  • 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
  • (2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid
Novel PSMB9 proteasome 20S subunit beta 9
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • CDT1 association with the CDC6:ORC:origin complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Carfilzomib
Novel SORBS2 sorbin and SH3 domain containing 2
Novel ZBTB42 zinc finger and BTB domain containing 42
BRCA1 BRCA1 DNA repair associated
  • Meiotic synapsis
  • SUMOylation of DNA damage response and repair proteins
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Transcriptional Regulation by E2F6
  • Meiotic recombination
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
  • Breast cancer
  • Ovarian cancer
COX20 cytochrome c oxidase assembly factor COX20
  • TP53 Regulates Metabolic Genes
  • Respiratory electron transport
DISC1 DISC1 scaffold protein
DUX4 double homeobox 4
DYNLL1 dynein light chain LC8-type 1
  • Activation of BIM and translocation to mitochondria
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Macroautophagy
  • MHC class II antigen presentation
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • Intraflagellar transport
  • RHO GTPases Activate Formins
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Mitotic Prometaphase
  • AURKA Activation by TPX2
  • HCMV Early Events
  • Aggrephagy
  • Aggrephagy
  • EML4 and NUDC in mitotic spindle formation
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
KATNA1 katanin catalytic subunit A1
KATNB1 katanin regulatory subunit B1
LINC01554 long intergenic non-protein coding RNA 1554
MTNR1B melatonin receptor 1B
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Ramelteon
  • Melatonin
  • Resveratrol
  • Agomelatine
  • Tasimelteon
  • Type II diabetes mellitus
NDEL1 nudE neurodevelopment protein 1 like 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation

Page 1 out of 2 pages